The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
% SDS-PAGE. Purity is greater than 98.0% as determined by analysis by RP-HPLC and SDS-PAGE.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Reconstitute in sterile 18MOhms/cm water to not less than 100 µg/ml, (which can then be further diluted to other aqueous solutions.)
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Goserelin is a synthetic decapeptide analogue of luteinising hormone-releasing hormone (LHRH).
On administration, initially, goserelin causes an increase in the amount of FSH and LH released from the pituitary gland. However, chronic administration of goserelin desensitises the pituitary gland. Eventually, after a period of about 14-21 days, production of LH is greatly reduced due to receptor downregulation, and sex hormones levels are reduced. This reduction in the levels of sex hormone can be exploited to treat disorders that are linked to levels of oestrogen or testosterone; such as prostate cancer, oestrogen dependant breast cancer, endometriosis and other benign gynaecological disorders.
References for Goserelin peptide (ab68486)
has not yet been referenced specifically in any publications.
Publishing research using ab68486? Please let us know so that we can cite the reference in this datasheet.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Get resources and offers direct to your inboxSign up